Evidence has shown that in colorectal cancer models, dual inhibition therapy targeting DNA methyltransferase and histone deacetylase (C02S, targeting HDAC1, 2, 3, 8) not only upregulates tumor ERV expression but also activates viral mimicry responses through the MDA5–MAVS signaling pathway. This evidence concerns the gene HDAC1 and colorectal cancer.